
Niraparib

Printed from https://www.cancerquest.org/node/6385 on 11/14/2026



Brand name: Zejula
IUPAC: 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
FDA approval: Yes
Manufacturer Link
Usage:

Niraparib is a once daily oral medication, which is mostly used in the treatment of ovarian cancers. It is also used in treatment of fallopian tube, or primary peritoneal cancers.1

1 TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about

Mechanism:

Niraparib works as a by inhibiting an enzym called poly ADP ribose polymerase (PARP). This process allows for the destruction of cancerous cell DNA, which in turns leads to apoptosis.1

Sphere Stick Line Cross Rotate

1 TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about

Side effects:

The most common side effects associated with niraparib include: nausea, low white and red blood cell counts, fatigue and constipation.1

1 TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about